Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma

Inhibitors of the Bromo‐ and Extra‐Terminal domain (BET) family proteins have strong preclinical antitumor activity in multiple tumor models, including lymphomas. Limited single‐agent activity has been reported in the clinical setting. Here, we have performed a pharmacological screening to identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Spriano, Filippo, Sartori, Giulio, Tarantelli, Chiara, Barreca, Marilia, Golino, Gaetanina, Rinaldi, Andrea, Napoli, Sara, Mascia, Michele, Scalise, Lorenzo, Arribas, Alberto J., Cascione, Luciano, Zucca, Emanuele, Stathis, Anastasios, Gaudio, Eugenio, Bertoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematologic Malignancy ‐ Lymphoid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422027/
https://www.ncbi.nlm.nih.gov/pubmed/36051080
http://dx.doi.org/10.1002/jha2.535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9422027/
https://www.ncbi.nlm.nih.gov/pubmed/36051080
http://dx.doi.org/10.1002/jha2.535

Ejemplares similares